Xspray Pharma: Dasynoc CRL – Initial Comments - Redeye

Redeye shares its initial comments on Xspray following the Dasynoc CRL. We see another unfortunate setback, but maintain an overall positive view of the long-term case. However, we will postpone launch and lower our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1026219/xspray-pharma-dasynoc-crl-initial-comments?utm_source=finwire&utm_medium=RSS